Literature DB >> 6115327

Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type.

P Davies, R D Terry.   

Abstract

The activity of choline acetyltransferase (ChAT) and the concentration of somatostatin-like immunoreactive material (SLI) have been measured in 8 brain regions from 12 normal individuals and 12 cases of presenile and senile dementia of the Alzheimer type. ChAT activity was significantly lower in all 8 brain regions of demented patients and the SLI concentration was significantly reduced in 7 of the the 8. There were correlations between the extent of the reductions of ChAT activity and SLI concentration in four brain regions, and a greater reduction of parietal cortex SLI in younger patients than in the more elderly.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6115327     DOI： 10.1016/0197-4580(81)90053-1

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  15 in total

1.  Effects of carbamazepine on cerebrospinal fluid somatostatin.

Authors:  D R Rubinow; R M Post; P W Gold; J C Ballenger; S Reichlin
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Somatostatin presynaptically inhibits both GABA and glutamate release onto rat basal forebrain cholinergic neurons.

Authors:  Toshihiko Momiyama; Laszlo Zaborszky
Journal:  J Neurophysiol       Date:  2006-03-29       Impact factor: 2.714

3.  Decrease in somatostatin-positive cell density in the amygdala of females with major depression.

Authors:  Gaelle Douillard-Guilloux; David Lewis; Marianne L Seney; Etienne Sibille
Journal:  Depress Anxiety       Date:  2016-08-24       Impact factor: 6.505

4.  Distribution of GABA and neuropeptides in the human cerebral cortex. A light and electron microscopic study.

Authors:  W Y Ong; L J Garey
Journal:  Anat Embryol (Berl)       Date:  1991

Review 5.  Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment.

Authors:  C G Gottfries
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

6.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

Authors:  H Cramer; D Schaudt; K Rissler; D Strubel; J M Warter; F Kuntzmann
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

8.  Lack of effect of chronic carbamazepine on brain somatostatin in the rat.

Authors:  S R Weiss; T Nguyen; D R Rubinow; C J Helke; P K Narang; R M Post; D M Jacobowitz
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients.

Authors:  D W Dickson; P Davies; R Mayeux; H Crystal; D S Horoupian; A Thompson; J E Goldman
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

10.  Loss of cortical GABA uptake sites in Alzheimer's disease.

Authors:  M D Simpson; A J Cross; P Slater; J F Deakin
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.